ENMD 2076

Drug Profile

ENMD 2076

Alternative Names: ENMD-2076; ENMD-981693; MKC-1693

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Miikana Therapeutics
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase A inhibitors; Fms-like tyrosine kinase 3 inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Multiple myeloma; Hepatocellular carcinoma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Hepatocellular carcinoma; Ovarian cancer; Soft tissue sarcoma
  • No development reported Acute myeloid leukaemia; Cancer; Haematological malignancies; Multiple myeloma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Canada (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Refractory metastatic disease) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top